Table 2.
Effect of pretreatment with rosiglitazone on serum alanine aminotransferase, tumor necrosis factor-α, IL-1β and IL-6 levels in rats after administration of lipopolysaccharide (n=6, mean ± SE)
| Sham + vehicle | BDL + vehicle | Sham + ROSI | BDL + ROSI | |
| ALT (U/L) | 78.6 ± 8.1 | 329.4 ± 40.5 | 42.3 ± 5.7a | 303.0 ± 46.6 |
| TNF-α (pg/mL) | 770.5 ± 52.5 | 2017.9 ± 167.5 | 517.0 ± 69.7a | 1984.0 ± 181.1 |
| IL-1β (pg/mL) | 1096.1 ± 101.7 | 2345.2 ± 194.7 | 648.4 ± 111.4a | 2226.7 ± 209.8 |
| IL-6 (pg/mL) | 4479.4 ± 377.4 | 10774.4 ± 675.4 | 2758.5 ± 497.7a | 9847.1 ± 865.1 |
a
P < 0.05 for vehicle (dimethyl sulfoxide) pretreatment vs rosiglitazone pretreatment group. BDL: Bile duct ligation; ROSI: Rosiglitazone; ALT: Alanine aminotransferase; TNF-α: Tumor necrosis factor-α.